Nantes, France – August 1, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the Company has received innovation aid of 200,000 euros from the French Government and the Pays de the Loire as part of the “France 2030” investment plan operated by Bpifrance.
Nicolas Poirier, CEO of OSE Immunotherapeutics, comments:
“We thank the French Government, the Pays de la Loire Region and Bpifrance for supporting us in the development of next-generation immunotherapies based on the unique assets that RNA Therapeutics could offer as a new first-in-class modality. Significant progress is underway to explore and define new frontiers of science in RNA therapies that pave the way for RNA-based immunotherapies targeting diseases that cannot be treated with other classes of conventional drugs. . OSE is building an unprecedented research platform, at the crossroads of antibody engineering, data science, artificial intelligence (AI) usually used by the OSE team, to which are now added the RNA Therapeutics and innovative RNA delivery methods recently patented by OSE to continue to develop next-generation immunotherapy treatments that modulate immune cell response in the fields of immuno-inflammation and immuno-oncology .